Background: eSource software that transfers patient electronic health record data into a clinical trial electronic case report form holds promise for increasing data quality while reducing data collection, monitoring and source document verification costs. Integrating eSource into multicenter clinical trial start-up procedures could facilitate the use of eSource technologies in clinical trials.

Methods: We conducted a qualitative integrative analysis to identify eSource site start-up key steps, challenges that might occur in executing those steps, and potential solutions to those challenges. We then conducted a value analysis to determine the challenges and solutions with the greatest impacts for eSource implementation teams.

Results: There were 16 workshop participants: 10 pharmaceutical sponsor, 3 academic site, and 1 eSource vendor representative. Participants identified 36 Site Start-Up Key Steps, 11 Site Start-Up Challenges, and 14 Site Start-Up Solutions for eSource-enabled studies. Participants also identified 77 potential impacts of the Challenges upon the Site Start-Up Key Steps and 70 ways in which the Solutions might impact Site Start-Up Challenges. The most important Challenges were: [1] not being able to identify a site eSource champion and [2] not agreeing on an eSource approach. The most important Solutions were: [1] eSource vendors accepting electronic data in the Health Level 7 Fast Healthcare Interoperability Resources (HL7® FHIR®) standard, [2] creating standard content for eSource-related legal documents, and [3] creating a common eSource site readiness checklist.

Conclusions: Site start-up for eSource-enabled multi-center clinical trials is a complex socio-technical problem. This study's Start-Up Solutions provide initial steps for scalable eSource implementation.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11625275PMC
http://dx.doi.org/10.1016/j.conctc.2024.101391DOI Listing

Publication Analysis

Top Keywords

site start-up
32
esource
12
esource site
12
start-up key
12
key steps
12
site
11
start-up
10
clinical trial
8
esource implementation
8
site esource
8

Similar Publications

Follicular dendritic cell-secreted protein (FDC-SP) is produced by follicular dendritic cells, periodontal ligament and junctional epithelium (JE). JE exists immediately apical to the bottom of the pocket and binds enamel with hemidesmosomes to protect the periodontium from bacterial infection. To analyze the transcriptional regulation of the FDC-SP gene by interleukin-6 (IL-6), we performed real-time PCR, Western blotting, immunofluorescence, luciferase (LUC) assays, gel mobility shift and chromatin immunoprecipitation (ChIP) assays using Ca9-22 and Sa3 gingival epithelial cells.

View Article and Find Full Text PDF

Background: Cancer radiotherapy (RT) still has limited clinical success because of the obstacles including radioresistance of hypoxic tumors, high-dose X-ray-induced damage to adjacent healthy tissue, and DNA-damage repair by intracellular PD-L1 in tumor.

Results: Therefore, to overcome these obstacles multifunctional core-shell BMS@PtAu nanoparticles (NPs) are prepared using nanoprecipitation followed by electrostatic assembly. PtAu clusters are released from BMS@PtAu NPs to alleviate tumor hypoxia by catalyzing the decomposition of endogenous HO to generate O as well as by enhancing X-ray deposition at the tumor site, which thereby reduce the required X-ray dose.

View Article and Find Full Text PDF

Interfacial Oxygen Vacancy of CuO-CeO Enhances HO Activation and Pollutant Degradation.

Chemistry

December 2024

School of Environmental Science and Engineering, Wuxi University, Jiangsu, 214105, P.R. China.

In the Fenton process, the development of catalysts with a wide pH range and good stability has been a long-term goal for water treatment purpose. This study proposes a strategy to solve this problem by preparing supported catalysts CuO@CeO-IE using an ion exchange reversed loading method. The generation of a large number of interfacial oxygen vacancies with Cu-O-Ce (O represents an oxygen vacancy site) structures prolongs the O-O bond of HO, promotes the rupture of the peroxide bond of HO, and thereby promotes the activation of HO on the surface of the catalyst.

View Article and Find Full Text PDF

Defining methods to improve eSource site start-up practices.

Contemp Clin Trials Commun

December 2024

Duke University, School of Medicine, Department of Medicine, Durham, NC, USA.

Background: eSource software that transfers patient electronic health record data into a clinical trial electronic case report form holds promise for increasing data quality while reducing data collection, monitoring and source document verification costs. Integrating eSource into multicenter clinical trial start-up procedures could facilitate the use of eSource technologies in clinical trials.

Methods: We conducted a qualitative integrative analysis to identify eSource site start-up key steps, challenges that might occur in executing those steps, and potential solutions to those challenges.

View Article and Find Full Text PDF
Article Synopsis
  • Fibroblast heterogeneity significantly impacts cancer progression, making it crucial to understand different fibroblast types for developing effective cancer treatments.
  • In pancreatic ductal adenocarcinoma (PDAC), cancer-associated fibroblasts (CAFs) are the predominant cell type, and the study identifies how the MAPK signaling pathway influences their differentiation into specific phenotypes.
  • The study introduces a novel "mapCAF" phenotype associated with certain tumor cells and immune response characteristics, suggesting that targeting these specific CAFs could improve treatment strategies for various cancers.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!